Screener
Crinetics Pharmaceuticals CRNX Employee Benefit Trust
Employee Benefit Trust at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesHeldInEmployeeTrust.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| STOCKHOLDERS’ EQUITY | ||
| Preferred stock, $0.001 par; 10,000 shares authorized; no shares issued or outstanding at March 31, 2026 or December 31, 2025 | — | — |
| Common stock and paid-in capital, $0.001 par; 200,000 shares authorized; 105,314 shares issued and outstanding at March 31, 2026; 95,575 shares issued and outstanding at December 31, 2025 | 2,828,204 | 2,407,757 |
| Accumulated other comprehensive (loss) income | (1,254) | 1,865 |
| Accumulated deficit | (1,545,272) | (1,417,427) |
| Stock held in trust | (1,032) | (112) |
| TOTAL STOCKHOLDERS’ EQUITY | 1,280,646 | 992,083 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $1,401,323 | $1,126,257 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's employee benefit trust?
- Crinetics Pharmaceuticals (CRNX) reported employee benefit trust of $1.03M in Q1 2026.
- What does employee benefit trust mean?
- This represents the value of assets held in a trust specifically designated to fund employee benefit programs or equity-based compensation plans. It functions as a mechanism to align employee interests with long-term shareholder value through deferred compensation structures. Changes in this balance reflect the company's strategy for talent retention and the funding status of its benefit obligations.
Ask your AI about Crinetics Pharmaceuticals's employee benefit trust.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude